# A Study to Investigate the Pharmacokinetic/Pharmacodynamic Characteristics of IBI128(A New Xanthine Oxidase Inhibitor)

> **NCT06277752** · PHASE1 · COMPLETED · sponsor: **Innovent Biologics (Suzhou) Co. Ltd.** · enrollment: 30 (actual)

## Conditions studied

- Gout Arthritis

## Interventions

- **DRUG:** dose-5 group
- **DRUG:** dose-1 group
- **DRUG:** dose-2 group
- **DRUG:** dose-4 group
- **DRUG:** dose-3 group

## Key facts

- **NCT ID:** NCT06277752
- **Lead sponsor:** Innovent Biologics (Suzhou) Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-03-05
- **Primary completion:** 2024-03-16
- **Final completion:** 2024-03-16
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2024-03-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06277752

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06277752, "A Study to Investigate the Pharmacokinetic/Pharmacodynamic Characteristics of IBI128(A New Xanthine Oxidase Inhibitor)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06277752. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*